Ad-hoc | 24 April 2001 08:21

Ad hoc-Service: STADA Arzneimittel AG english

Ad hoc announcement transmitted by DGAP. The issuer has the sole responsibility of this announcement. ——————————————————————————– STADA: Record results and growth forecast – Conversion of preferred stock to common stock planned In publishing its results for the fiscal year 2000 STADA Arzneimittel AG presents its fifth record year in a row. The earnings before interest, taxes and depreciation (EBITDA) for the Group reached DM 106.1 million, an increase of +43% compared to the previous years figure of DM 74.0 million. After adjusting for one-time extraordinary expenses of DM 6.9 million in connection with the capital increase, and with the floating of a warrant issue in May of 2000, the consolidated net earnings come to DM 36.0 million – an increase of +63% over the figure of DM 22.1 million for the previous year. Sales increased by +32% to DM 913.7 million (previous year: DM 692.9 million). Twenty-four percent-points of the growth in sales can be attributed to organic growth, and eight percent- points to acquisitions. The Executive Board expects the dynamic growth to continue in the current fiscal year 2001, with sales of DM 1.1 billion which will clearly top the billion threshold for sales. The EBITDA is also expected to increase by double-digit percentages. The trend in STADAs sales in the first three months confirm this prognosis. The sales growth of about +16% in the first quarter of 2001 falls within the planning range, and makes the expected sales increase of +20% for the entire fiscal year 2001 appear realistic. (The final results for the 1st quarter of 2001 will be published on May 11, 2001.) At the shareholders meeting on June 19, 2001 the Executive Board and the Supervisory Board will propose to the shareholders that the preferred stock be converted to registered common stock. That is in pursuit of the goal of increasing the liquidity of STADAs stock by concentrating on one category of shares. For further information please contact: STADA Arzneimittel AG / Corporate Communication / 61118 Bad Vilbel Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail: communication@stada.de Or visit us on the Internet at www.stada.de. end of ad hoc announcement, (c) DGAP 24.04.2001 ——————————————————————————– WKN: 725180; Index: SDax Listed: Amtlicher Handel in Frankfurt (SMAX) und Düsseldorf; Freiverkehr in Berlin, Hamburg, München und Stuttgart 240821 Apr 01